MSBase & BigMS Harmonized Cohort: Quantifying Progression Independent of Relapse Activity (PIRA) Under High-Efficacy DMTs
Study Design & Technical Specifications
Sample Size / Cohort
48,000+ Longitudinal MS Patients
Subject / Study Model
Human Clinical Cohort
Analytical Modalities
Primary Abstract & Repository Description
Source: MS Data AllianceEditorial Critique, Methodological Value & Reusability Guide
1. Scientific Context & Premise
Primary Premise (MS Data Alliance): "Multi-center longitudinal real-world evidence study evaluating roving-baseline EDSS trajectories, Relapse-Associated Worsening (RAW) versus PIRA rates, and early anti-CD20 / natalizumab intervention across harmonized international MS registries." Within Multiple Sclerosis (MS), this work examines Multiple Sclerosis, PIRA, EDSS, MSBase, Real-World Evidence in relation to paramagnetic rim lesions (PRLs), T2/FLAIR lesion volume, oligoclonal bands, EBV titers, and EDSS progression metrics. Authored by Kalincik T, Butzkueven H, Tur C.
2. Study Architecture & Findings
Study Architecture: Human Clinical Cohort (48,000+ Longitudinal MS Patients) utilizing Longitudinal EDSS, Clinical Metrics, OMOP CDM [DOI: 10.1001/jamaneurol.2022.4655]. Key reported conclusion: "Multi-center longitudinal real-world evidence study evaluating roving-baseline EDSS trajectories, Relapse-Associated Worsening (RAW) versus PIRA rates, and early anti-CD20 / natalizumab intervention across harmonized international MS registries."
3. Secondary Analysis & Reusability
Secondary Analysis Applications: (1) Cross-referencing Longitudinal EDSS, Clinical Metrics, OMOP CDM variables (Multiple Sclerosis, PIRA, EDSS, MSBase, Real-World Evidence) against open repositories in Multiple Sclerosis (MS); (2) Benchmarking feature distributions and effect sizes reported in "MSBase & BigMS Harmonized Cohort: Quantifying Progression Independent of Relapse"; (3) Informing cohort stratification and endpoint selection.
4. Methodological Caveats & Governance
Methodological Note: When integrating these Longitudinal EDSS, Clinical Metrics, OMOP CDM findings, account for cohort-specific inclusion criteria (48,000+ Longitudinal MS Patients), potential site/instrument batch effects, and repository license terms (MSBase DUA / Academic Consortium).
Data Access, Reproducibility & Analysis Starter Guide
FAIR Open Science & Clinical Metadata Verification Protocol
Quick Data Access & Structured Export
Open the primary repository directly or download structured metadata (JSON / CSV) in one click.
This resource is indexed under FAIR (Findable, Accessible, Interoperable, and Reusable) open-science metadata standards, enabling programmatic cross-referencing across Europe PMC, Semantic Scholar, ClinicalTrials.gov, and CNS Open Data.
Programmatic Data Retrieval (Python Starter Code & Recommended SDKs)
Python Quickstart: Query Europe PMC & Semantic Scholar Metadata
# Fetch structured bibliographic & open-access data via Europe PMC REST API
import urllib.request
import urllib.parse
import json
query = "DOI:\"10.1001/jamaneurol.2022.4655\""
url = f"https://www.ebi.ac.uk/europepmc/webservices/rest/search?query={urllib.parse.quote(query)}&format=json&resultType=core"
with urllib.request.urlopen(url, timeout=10) as response:
payload = json.loads(response.read().decode("utf-8"))
results = payload.get("resultList", {}).get("result", [])
if results:
record = results[0]
print("Title:", record.get("title"))
print("Journal / Source:", record.get("journalTitle") or record.get("bookOrReportDetails"))
print("Cited By Count:", record.get("citedByCount", 0))Standardized 4-Step Workflow & Governance Checklist
Standardized Acquisition & Preprocessing Workflow
1. Programmatic Metadata & Full-Text OA Retrieval
Query Europe PMC or Crossref REST APIs using the persistent DOI/URL to retrieve structured XML full text, supplementary tables, and grant links.
2. Study Design & Cohort Eligibility Screening
Extract sample size, inclusion/exclusion criteria, and primary outcome endpoints for systematic review (PRISMA) inclusion.
3. Data Availability & Supplementary Repository Linkage
Locate accession numbers (GEO, SRA, OpenNeuro, DANDI, Zenodo, Figshare) referenced in the Data Availability section.
4. Citation Graph & Replication Tracking
Monitor supporting and contrasting citations over time to verify whether key findings have been independently replicated.
Reproducibility & Governance Checklist
- Verify whether the source is a peer-reviewed journal publication or an unrefereed preprint before clinical citation.
- Check supplementary data licenses (CC-BY / CC0) when extracting figures or summary statistics for meta-analyses.
- Cross-reference NCT clinical trial identifiers when evaluating therapeutic efficacy or biomarker endpoints.
Tags & Modalities
Bibliometrics, Peer-Review Status & Citation Export
Cross-referenced via Semantic Scholar, Europe PMC & bioRxiv
1. Citation Metrics & Context Breakdown
Citation Context Breakdown
2. Peer-Review Validation & Revision History
Verified Publication / Open Dataset Record
Metadata and license integrity verified against primary repository records.
3. Standardized Academic Citation & BibTeX Export
Kalincik T et al. (2026). MSBase & BigMS Harmonized Cohort: Quantifying Progression Independent of Relapse Activity (PIRA) Under High-Efficacy DMTs. MS Data Alliance. https://doi.org/10.1001/jamaneurol.2022.4655
@article{t2026msba,
title = {MSBase & BigMS Harmonized Cohort: Quantifying Progression Independent of Relapse Activity (PIRA) Under High-Efficacy DMTs},
author = {Kalincik T and Butzkueven H and Tur C and MSBase Study Group},
year = {2026},
journal = {MS Data Alliance},
howpublished = {\url{https://www.msbase.org/}},
doi = {10.1001/jamaneurol.2022.4655},
note = {CNS Open Data: multiple_sclerosis}
}Related Multiple Sclerosis Research & Datasets
Explore All DatasetsMSDA: COVID19 GDSI LocalDashboard - Federated MS Data Toolkit
Official open-source repository and tool for Multiple Sclerosis federated research and data harmonization under MS-DATA-ALLIANCE.
Global Data Sharing Initiative (GDSI): Containerized Federated Analysis Pipeline for MS Registries
International federated research initiative and containerized query framework allowing participating national MS registries to analyze disease-modifying therapy (DMT) safety, anti-CD20 outcomes, and PIRA progression without transferring identifiable patient data.
Multiple Sclerosis and Viruses: « Liaisons Dangereuses ».
Multiple sclerosis (MS) is a complex, multifactorial neurodegenerative disease with an aetiology that is still partially elusive. Several risk factors are associated with MS development including genetic predisposition and various environmental stressors; however, recently, viral infections have gained significant attention as a crucial environmental trigger. Despite the well-established link between Epstein-Barr virus (EBV) and MS susceptibility, a single-pathogen model fails to clearly characterise the molecular cascades driving the disease, suggesting that the transition from infection to autoimmune response involves more than one viral agent. In this review we examine the speculation that the interactions among different neurotropic viruses could serve a collective causative role in MS, which is under-researched in the literature at present. We summarise contradictory evidence on the role of different viral agents, including the Herpesviridae family (Human Cytomegalovirus, EBV, Herpes Simplex Viruses HSV-1 and HSV-2, and Varicella Zoster Virus), Paramyxoviridae family (Measles Virus and Rubella Virus), Influenza virus, SARS-CoV-2, and Human Endogenous Retroviruses (HERVs). Through interplay within shared molecular pathways, immune modulation, and activation of latent infections, these viruses may collectively influence the inflammatory and demyelinating processes that characterise MS. This review evaluates the etiological role of viral interplay in MS through the cumulative and interactive effects of these pathogens. The available epidemiological, immunological, and experimental data converge on the concept that viral co-exposures act synergistically to shape MS susceptibility in genetically predisposed individuals. Characterising these viral interactions presents a new research direction for the identification of novel biomarkers and the development of preventative strategies through the targeted control of viral networks.
CNM-Au8 Treatment Is Associated With Reduced Chronic Lesion Tissue Expansion in Relapsing-Remitting Multiple Sclerosis
BackgroundCNM-Au8, a catalytic nanocrystalline gold suspension, is proposed to support neuronal bioenergetics, but its effect on chronic lesion evolution in multiple sclerosis (MS) has not been reported. ObjectivesTo evaluate the effect of CNM-Au8 on chronic lesion tissue expansion (CLTE). Results...
MSDA Core Dataset (CDS): Standardized Global Real-World Data Harmonization Framework for Multiple Sclerosis
The MSDA Core Dataset (CDS) establishes a 44-variable international harmonization schema mapped to the OMOP Common Data Model, enabling privacy-preserving federated analytics across global Multiple Sclerosis registries.
MSDA Global Registry & Cohort Metadata Discovery Catalogue (BigMS Network)
A centralized metadata discovery catalogue indexing over 30 national and international MS registries (>120,000 patients), detailing variable availability for EDSS, relapse history, MRI, fluid biomarkers, and DUA governance.
Active Clinical Trials & Pipeline in Multiple Sclerosis
View Clinical PipelineMSBase & BigMS Harmonized Cohort: Quantifying Progression Independent of Relapse Activity (PIRA) Under High-Efficacy DMTs
Global Data Sharing Initiative (GDSI): Containerized Federated Analysis Pipeline for MS Registries
MSDA: GDSI Mock DataGenerator - GDSI Mock data generator
Related Data & Resources
Academic Research & Medical Information Disclaimer
This page provides structured scientific metadata, methodological critiques, and open-data reusability guidelines intended strictly for neuroscience researchers and data scientists. It does not constitute medical advice, clinical diagnosis, or treatment recommendations.
Was this resource helpful?
Help improve data curation by sharing your feedback.